Rettospective clinical analysis and pathological singificance of biomarkers for astrocytoma progression

Abstract

Astrocytoma’s are the most common malignancies of the brain. World Health Organization (WHO) has classified astrocytoma in four grades (Grade I- pilocytic astrocytoma, Grade II- diffuse astrocytoma, Grade III- anaplastic astrocytoma and Grade IV- glioblastoma multiforme) on account of cellularity, nuclear polymorphism, mitotic index, microvascular proliferation and extent of necrosis [1]. However recent scheme of classification based on the co-expression modules around most mutated gene such as receptor tyrosine kinases are proposed to accurately assign prognosis in astrocytoma cases[2]. Grade IV astrocytoma also referred as glioblastoma multiformae (GBM), are the most aggressive primary tumours with worst prognosis and account for nearly 60% of malignant gliomas [3-5]. The overall prognosis for malignant glial tumours have not changed significantly since 1980 despite of advancements in course of diagnosis and mode of treatment